Literature DB >> 2195479

Amphotericin B. Still the 'gold standard' for antifungal therapy.

G A Sarosi1.   

Abstract

Amphotericin B (Fungizone) remains the cornerstone of antifungal therapy because of its broad-spectrum fungicidal activity and rapid onset of action. Ketoconazole (Nizoral) and the new triazoles are welcome additions to the therapeutic armamentarium but do not replace amphotericin B. Adverse side effects of amphotericin B treatment are usually manageable and often preventable. Careful attention to detail reduces immediate toxicity and allows completion of the desired therapeutic course without an undue risk of permanent nephrotoxicity.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2195479     DOI： 10.1080/00325481.1990.11716368

Source DB:  PubMed          Journal:  Postgrad Med        ISSN： 0032-5481            Impact factor:   3.840


  12 in total

1.  Comparative Ploidy Proteomics of Candida albicans Biofilms Unraveled the Role of the AHP1 Gene in the Biofilm Persistence Against Amphotericin B.

Authors:  Thuyen Truong; Guisheng Zeng; Lin Qingsong; Lim Teck Kwang; Cao Tong; Fong Yee Chan; Yue Wang; Chaminda Jayampath Seneviratne
Journal:  Mol Cell Proteomics       Date:  2016-09-19       Impact factor: 5.911

2.  Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.

Authors:  R Petraitiene; V Petraitis; A H Groll; T Sein; S Piscitelli; M Candelario; A Field-Ridley; N Avila; J Bacher; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

3.  Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.

Authors:  R Petraitiene; V Petraitis; A H Groll; M Candelario; T Sein; A Bell; C A Lyman; C L McMillian; J Bacher; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

4.  Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Andreas H Groll; Kristin Roussillon; Melissa Hemmings; Caron A Lyman; Tin Sein; John Bacher; Ihor Bekersky; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

5.  Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats.

Authors:  R M Fielding; P C Smith; L H Wang; J Porter; L S Guo
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 6.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

7.  Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants.

Authors:  M A Amantea; R A Bowden; A Forrest; P K Working; M S Newman; R D Mamelok
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 8.  Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.

Authors:  Chris Stockmann; Jonathan E Constance; Jessica K Roberts; Jared Olson; Elizabeth H Doby; Krow Ampofo; Justin Stiers; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

9.  In vitro susceptibility to 9 antifungal agents of 14 strains of Zygomycetes isolated from clinical specimens.

Authors:  M Otcenásek; V Buchta
Journal:  Mycopathologia       Date:  1994-12       Impact factor: 2.574

10.  Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Caron A Lyman; Andreas H Groll; Diana Mickiene; Joanne Peter; John Bacher; Kristin Roussillon; Melissa Hemmings; Derrek Armstrong; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.